You are here


Thalidomide Analogs that Inhibit Inflammation and Angiogenesis

Primary tabs

The National Cancer Institute seeks parties interested licensing or collaborative research to co-develop thalidomide analogs to treat cancer and inflammatory diseases.
NIH Reference Number
Product Type
  • thalidomide, lenalidomide, pomalidomide
  • anti-angiogenesis, anti-inflammatory
Collaboration Opportunity
This invention is available for licensing and co-development.
Description of Technology

Thalidomide and its close analogs (lenalidomide and pomalidomide) are widely used to treat a variety of diseases, such as multiple myeloma and other cancers as well as the symptoms of several inflammatory disorders. However, thalidomide is known for its teratogenic adverse effects when first clinically introduced in the 1950s, and is associated with drowsiness and peripheral neuropathy. Hence, there is intense interest to synthesize, identify and develop safer analogs. 

Researchers at the National Cancer Instituten synthesized novel thalidomide analogs that demonstrate clinical potential without being teratogenic, as initially evaluated in in vivo zebrafish and chicken embryo model systems and in cell culture.  These new compounds differentially provide potent anti-angiogenesis and/or anti-inflammatory action. The agents have potential for development of new cancer therapies and treatment of a number of  neurological and systemic disorders involving chronic inflammation and elevated TNF-alpha levels.

Potential Commercial Applications

- Cancer therapeutics
- Inflammatory disorders such as Crohn's disease, sarcoidosis, graft-versus-host disease, and rheumatoid arthritis
- Neuroinflammatory disorders (acute: traumatic brain injury and stroke; chronic: Parkinson's disease, Alzheimer's disease, multiple sclerosis)

Competitive Advantages

- Non-teratogenic
- Potent


Nigel H. Greig (NIA), Weiming Luo (NIA), David Tweedie (NIA), William Douglas Figg Sr. (NCI), Neil Vargesson (Univ. Aberdeen, Scotland), Shaunna Beedie (Univ. Aberdeen, Scotland)

Development Stage
Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number 62/235, 10, Filed 30 Sep 2015
  • U.S. Patent Issued: U.S. Patent Number 10,836,721, Issued 17 Nov 2020
Therapeutic Area
Tuesday, January 26, 2021